Apricus Biosciences 2016 LD Micro Investor Presentation

Apricus Biosciences presented at the 9th Annual LD Micro Main Event in December 2016, discussing patient-centered drug development in urology and rheumatology. The company outlined milestones for Vitaros, including a planned U.S. NDA re-submission in late 2017 and potential approval and launch in 2018, along with development opportunities for its RayVa product candidate.